IMNM vs. IGMS, VIR, AIMT, CRNX, PRGO, CORT, AXSM, RARE, HCM, and PBH
Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include IGM Biosciences (IGMS), Vir Biotechnology (VIR), Aimmune Therapeutics (AIMT), Crinetics Pharmaceuticals (CRNX), Perrigo (PRGO), Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), Ultragenyx Pharmaceutical (RARE), HUTCHMED (HCM), and Prestige Consumer Healthcare (PBH). These companies are all part of the "medical" sector.
Immunome (NASDAQ:IMNM) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
Immunome has a net margin of -1,829.44% compared to IGM Biosciences' net margin of -11,255.25%. Immunome's return on equity of -37.33% beat IGM Biosciences' return on equity.
IGM Biosciences received 38 more outperform votes than Immunome when rated by MarketBeat users. However, 69.44% of users gave Immunome an outperform vote while only 48.84% of users gave IGM Biosciences an outperform vote.
In the previous week, Immunome had 4 more articles in the media than IGM Biosciences. MarketBeat recorded 4 mentions for Immunome and 0 mentions for IGM Biosciences. Immunome's average media sentiment score of 0.82 beat IGM Biosciences' score of 0.00 indicating that Immunome is being referred to more favorably in the media.
44.6% of Immunome shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 8.6% of Immunome shares are owned by company insiders. Comparatively, 57.0% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Immunome has higher revenue and earnings than IGM Biosciences. Immunome is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
Immunome presently has a consensus target price of $29.80, indicating a potential upside of 96.05%. IGM Biosciences has a consensus target price of $17.89, indicating a potential upside of 117.63%. Given IGM Biosciences' higher probable upside, analysts plainly believe IGM Biosciences is more favorable than Immunome.
Immunome has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.
Summary
Immunome beats IGM Biosciences on 12 of the 18 factors compared between the two stocks.
Get Immunome News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunome Competitors List
Related Companies and Tools
